SANTA BARBARA, Calif., Dec. 7 /PRNewswire/ -- Izalex Incorporated today announced the appointment of Keith B. Hoffman, Ph.D. as Vice President Corporate Development and Malcolm Casale, Ph.D. as Director NeuroGraph Development. Drs. Hoffman and Casale were both employed by Thuris Corporation from whom Izalex acquired all rights to the NeuroGraph technology. Drs. Hoffman and Casale will be based in the company’s Irvine facility.
“I am thrilled that Izalex was able to bring Keith and Malcolm onto our team. They are both exceptionally talented individuals that will drive corporate development and NeuroGraph technology enhancement activities respectively,” said R. Scott Greer, Chairman and CEO of Izalex Incorporated.
Dr. Keith B. Hoffman is Vice President of Corporate Development of Izalex and Chief Operating Officer of Thuris. Prior to joining Thuris he was the head of drug selection and intellectual property at Ancile Pharmaceuticals. Dr. Hoffman was a co-founder of Microislet (microencapsulation of pancreatic islet cells as a cure for insulin-dependent diabetes), SkipRack (internet commerce), and OLAS Pharmaceuticals (therapeutics to combat hormone deficiencies). Dr. Hoffman received his Ph.D. from Professor Gary Lynch at UC Irvine for his work on the biochemistries underlying memory formation, Alzheimer’s disease, and epilepsy.
Dr. Malcolm S. Casale is responsible for all the technical aspects of the NeuroGraph systems. Prior to joining Thuris, he was Vice President of R&D at Knowledge Foundations (knowledge basis for pharmaceutical and other businesses). Prior to this, Dr. Casale served for 18 years, and was chief technologist, at MSC Software (software for large-scale engineering stress and other simulations). Dr. Casale received his Ph.D. in engineering at the University of California, Irvine in 1989 and returned in 1998 for a second Ph.D. in computational biology.
About Izalex
Izalex was formed to develop and commercialize innovative medical devices that assist physicians in diagnosing and treating psychiatric disorders. The company’s product portfolio is based on its proprietary NeuroGraph(R) technology. The NeuroGraph is a portable, turnkey hardware and software system that enables a doctor to run an approximately 20 minute, non-invasive session eliciting detailed electrophysiological data from a patient. Powered by proprietary analytical algorithms, the NeuroGraph compares the patient’s response to proprietary databases of normal and patient populations. The software then outputs a diagnostic classification of the patient with a high degree of accuracy. More information on the company and its principals can be found at the company website http://www.izalex.com/.
Izalex Incorporated
CONTACT: R. Scott Greer, Chairman and CEO of Izalex, +1-805-969-9395,scott.greer@izalex.com
Web site: http://www.izalex.com/